产品/疗法

黑色素瘤和实体瘤中自体细胞治疗年度重大进展

Top advances of the year in autologous cellular therapy in melanoma and solid tumors.

肉瘤细胞治疗的演变：突破、挑战与未来方向

The evolution of cellular therapies in sarcoma: Breakthroughs, challenges, and future directions.

实体瘤中的细胞治疗：我们准备好进入黄金时段了吗？

Cellular Therapies in Solid Tumors: Are We Ready for Primetime?

突变选择性 T 细胞受体疗法用于实体瘤

Mutant Selective T-Cell Receptor Therapy for Solid Tumors.

实体瘤细胞治疗进展：欧洲视角与未来方向

Advances in cell therapy for solid tumours: European perspective and future directions.

肉瘤细胞治疗：现状与未来方向

Cell therapy in sarcoma: current landscape and future directions.

afamitresgene autoleucel 治疗晚期滑膜肉瘤和黏液样圆细胞脂肪肉瘤的评估

An evaluation of afamitresgene autoleucel for the treatment of advanced synovial sarcoma and myxoid round cell liposarcoma.

Afami-cel 是肉瘤治疗的一个里程碑，为工程化 TCR T 细胞疗法在实体瘤中的应用确立了概念验证。

儿童软组织肉瘤的最新进展

Update on pediatric soft tissue sarcomas.

推进基于人类白细胞抗原的癌症免疫治疗：从个性化到针对遗传异质性人群的广谱策略

Advancing human leukocyte antigen-based cancer immunotherapy: from personalized to broad-spectrum strategies for genetically heterogeneous populations

肉瘤中的过继性 T 细胞疗法

Adoptive T-Cell Therapy in Sarcomas.

FDA 批准摘要：Afamitresgene Autoleucel 用于既往接受过化疗的 HLA 限制性、MAGE-A4 阳性不可切除或转移性滑膜肉瘤成人患者

FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prio

肉瘤及其他实体瘤中的细胞治疗

Cellular therapies in sarcoma and other solid tumors.

过继性细胞疗法治疗肉瘤的综述

Review of Adoptive Cellular Therapies for the Treatment of Sarcoma.

Afamitresgene autoleucel：首个用于滑膜肉瘤的细胞疗法

Afamitresgene autoleucel: first cell therapy for synovial sarcoma.

拓展 CAR-T 细胞与双特异性 T 细胞衔接器在实体瘤中的治疗覆盖范围

Expanding the Therapeutic Reach of Chimeric Antigen Receptor T-Cells and Bispecific T-Cell Engagers Across Solid Tumors.

CAR-T 细胞与过继性 T 细胞疗法在淋巴及实体器官恶性肿瘤中的综述

A Review of CAR T Cells and Adoptive T-Cell Therapies in Lymphoid and Solid Organ Malignancies.

Afamitresgene Autoleucel：首次批准

Afamitresgene Autoleucel: First Approval.

简讯：Afamitresgene autoleucel（Tecelra）用于滑膜肉瘤

In brief: Afamitresgene autoleucel (Tecelra) for synovial sarcoma.

Afamitresgene autoleucel 用于晚期滑膜肉瘤和黏液样圆细胞脂肪肉瘤（SPEARHEAD-1）：一项国际性、开放标签、2 期试验

Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial.

Afami-cel 治疗在既往接受过大量治疗、HLA-A*02 阳性且表达 MAGE-A4 的滑膜肉瘤患者中产生了持久缓解。本研究表明，T 细胞受体疗法可有效靶向实体瘤，并为将这一方法扩展至其他实体恶性肿瘤提供了依据。

低剂量放疗联合 MAGE-A4 T 细胞治疗后 HLA-A2+ 难治性黑色素瘤患者转移灶的持久控制：病例报告

Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a